姓名：李念光
職稱：教授
E-mail：linianguang@163.com
主要研究方向：血液腫瘤新藥物分子發現及優化
個人簡介
李念光，教授，博士生導師，現任bevictor伟德官网副院長，江蘇省藥學會藥物化學專業委員會委員，南京市藥學會藥物化學與藥物分析專業委員會副主任委員。2007年博士畢業于中國藥科大學，2012年赴美國哈佛大學進行訪學和合作研究。2011年入選江蘇省333人才培養第三層次培養對象，2012年入選“教育部新世紀優秀人才支持計劃”，2013年入選江蘇省第十批“六大人才高峰”，2013年獲教育部霍英東青年教師獎三等獎。近年來主要從事血液腫瘤新藥物分子的設計與合成研究，主持10多項國家及省部級項目，在Journal of Experimental & Clinical Cancer Research、Journal of Medicinal Chemistry、European Journal of Medicinal Chemistry等雜志發表SCI論文100餘篇。申請國家發明專利11項，授權9項。指導本科生獲大學生“挑戰杯”課外學術競賽國家級二等獎2項，研究生獲江蘇省優秀畢業論文1次，擔任本科教學《藥物化學》、《藥物合成》以及研究生教學《藥物化學專論》、《藥物合成化學》課程負責人。
承擔的主要科研項目
1. 國家自然科學基金面上項目（82373710），新型構象穩定的大環類FLT3抑制劑的設計、合成與抑制門控卡口氨基酸F691L突變導緻的急性髓性白血病耐藥活性研究，2024/01-2027/12，主持，49萬
2. 國家自然科學基金面上項目（81973171），基于結構的新型選擇性FLT3共價抑制劑的設計、合成及其對（複發性及預後不良）急性髓性白血病的生物活性研究，2020/01-2023/12，主持，55萬
3. 國家重點研發計劃子課題（2020YFA0509404），靶向肝、肺轉移定植中特化外秘體活性小分子探針的發現和幹預研究，2020/11-2025/10，主持，20萬
4. 江蘇省自然科學基金（BK20151563），治療阿爾茨海默病的新型多靶向BACE1抑制劑的設計、合成及其作用機制研究，2015/07-2018/06，主持，10萬
5. 江蘇省第十批“六大人才高峰”項目A類資助（2013-YY-010），以天然産物為模闆的新型凝血酶抑制劑的設計、合成與生物活性研究，2014/01-2016/12，主持，15萬
6. 教育部新世紀優秀人才支持計劃（NCET-12-0741），天然産物的化學合成及其構效關系，2013/01-2015/12，主持，50萬
7. 國家自然科學基金（81001382），基于體内代謝機制的燈盞乙素苷元結構修飾、構效關系及生物利用度研究，2011/01-2013/12，主持，21萬
代表性論文
1. Yan-Cheng Yu, Zhen-Jiang Tong, Xiao-Ting Liang, Jia-Zhen Wu, Yu-Jing Xu, Jing-Jing Wang, Meng-Yuan Zhang, Tian-Hua Wei, Jin Yang, Yi-Bo Wang, Qing-Xin Wang, Qing-Qing Li, Zi-Xuan Wang, Xue-Jiao Leng, Ning Ding, Xin Xue, Shan-Liang Sun, Nian-Guang Li*, XiaoLong Wang*. Discovery of RORγ Allosteric Fluorescent Probes and the Application: Fluorescence Polarization, Screening and Bioimaging. Journal of Medicinal Chemistry, 2024, 67(5), 4194−4224. (IF 7.300)
2. Zi-Xuan Wang, Qing-Qing Li, Jiao Cai, Jia-Zhen Wu, Jing-Jing Wang, Meng-Yuan Zhang, Qing-Xin Wang, Zhen-Jiang Tong, Jin Yang, Tian-Hua Wei, Yun Zhou, Wei-Chen Dai, Ning Ding, Xue-Jiao Leng, Shan-Liang Sun, Xin Xue, Yan-Cheng Yu*, Ye Yang*, Nian-Guang Li*, Zhi-Hao Shi*. Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.Journal of Medicinal Chemistry, 2024, 67(6), 6, 4346-4375. (IF 7.300)
3. Shan-Liang Sun, Shi-Han Wu, Ji-Bo Kang, Yi-Yuan Ma, Lu Chen, Peng Cao,* Liang Chang, Ning Ding, Xin Xue,* Nian-Guang Li,* and Zhi-Hao Shi* Medicinal chemistry strategies for the development of Bruton’s tyrosine kinase inhibitors against resistance. Journal of Medicinal Chemistry, 2022, 65, 7415−7437. (IF 7.300)
4. Yue Zhong, Run-Ze Qiu, Shan-Liang Sun,* Chao Zhao, Tian-Yuan Fan, Min Chen, Nian-Guang Li,* Zhi-Hao Shi*. Small-molecule Fms-like tyrosine kinase 3 inhibitors: An attractive and efficient method for the treatment of acute myeloid leukemia. Journal of Medicinal Chemistry, 2020, 63(21), 12403−12428. (IF 7.300)
5. Chunyan Gu, Yajun Wang, Lulin Zhang, Li Qiao, Shanliang Sun, Miaomiao Shao, Xiaozhu Tang, Pinggang Ding, Chao Tang, Yuhao Cao, Yanyan Zhou, Mengjie Guo, Rongfang Wei, Nianguang Li*, Yibei Xiao*, Jinao Duan*, Ye Yang*. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma. Journal of Experimental & Clinical Cancer Research, 2022, 41:11. (IF 11.300)
6. Shan-Liang Sun, Jia-Zhen Wu, Jing-Jing Wang, Hai Zhou, Chen-Qian Zhang, Zhen-Jiang Tong, Yi-Bo Wang, Jiu-Kai Sha, Qing-Xin Wang, Jia-Chuan Liu, Xin-Rui Zheng, Qing-Qing Li, Meng-Yuan Zhang, Jin Yang, Tian-Hua Wei, Zi-Xuan Wang, Yan-Cheng Yu, Ning Ding, Xue-Jiao Leng, Xin Xue, He-Min Li, Wei-Chen Dai, Xiao-Ying Yin, Ye Yang*, Jin-Ao Duan*, Nian-Guang Li*, Zhi-Hao Shi*. Preclinical Characterization of Danatinib as a Novel FLT3 Inhibitor with Excellent Efficacy Against Resistant Acute Myeloid Leukemia. Biomedicine & Pharmacotherapy, 2023, 169, 115905. (IF 7.500)
7. Jiaojiao Wang, Dihui Xu, Lili Shen, Jing Zhou, Xiang Lv, Hongyue Ma*, Nianguang Li*, Qinan Wu, Jinao Duan. Anti-inflammatory and analgesic actions of bufotenine through inhibiting lipid metabolism pathway. Biomedicine & Pharmacotherapy, 2021, 140, 111749. (IF 7.500)
8. Qing-Xin Wang, Peng-Yu Zhang, Qing-Qing Li, Zhen-Jiang Tong, Jia-Zhen Wu, Shao-Peng Yu, Yan-Cheng Yu, Ning Ding, Xue-Jiao Leng, Liang Chang, Jin-Guo Xu, Shan-Liang Sun*, Ye Yang*, Nian-Guang Li*, Zhi-Hao Shi*. Challenges for the Development of Mutant Isocitrate Dehydrogenases 1 Inhibitors to Treat Glioma. European Journal of Medicinal Chemistry, 2023, 257, 115464. (IF 6.700)
9. Jing-Han Zhao, Yue-Wei Wang, Jin-Yang, Zhen-Jiang Tong, Jia-Zhen Wu, Yi-Bo Wang, Qing-Xin Wang, Qing-Qing Li, Zi-Xuan Wang, Yan-Cheng Yu, Xue-Jiao Leng, Liang Chang, Xin Xue, Shan-Liang Sun, He-Min Li, Chun-Lei Xu, Ning Ding*, Jin-Ao Duan*, Nian-Guang Li*, Zhi-Hao Shi*. Natural products as potential lead compounds to develop new antiviral drugs over the past decade. European Journal of Medicinal Chemistry, 2023, 260, 115726. (IF 6.700)
10. Xin Xue, Ji-Bo Kang, Xiao Yang, Nan Li, Liang Chang*, Juan Ji, Xiang-Kai Meng, Hai-Qing Zhang, Yue Zhong, Shao-Peng Yu, Wen-Yu Wu, Xiao-Long Wang, Nian-Guang Li*, Shan-Liang Sun*. An efficient strategy for digging protein-protein interactions for rational drug design–A case study with HIF-1α/VHL. European Journal of Medicinal Chemistry, 2022, 227, 113871. (IF 6.700)
